Neutrophil-to-lymphocyte ratio, Factor VIII and Antithrombin III: inflammatory-clotting biomarkers in glioma.
Antithrombin III
Factor VIII
biomarker
coagulation
glioblastoma
glioma
inflammation
neutrophil-to-lymphocyte ratio
Journal
EXCLI journal
ISSN: 1611-2156
Titre abrégé: EXCLI J
Pays: Germany
ID NLM: 101299402
Informations de publication
Date de publication:
2021
2021
Historique:
received:
30
04
2021
accepted:
02
07
2021
entrez:
4
8
2021
pubmed:
5
8
2021
medline:
5
8
2021
Statut:
epublish
Résumé
One of the key difficulties in glioma treatment is our limited ability to consistently assess cancer response or progression either by neuroimaging or specific blood biomarkers. An ideal biomarker could be measured through non-invasive methods such as blood-based biomarkers, aiding both early diagnosis and monitoring disease evolution. This is a single-center, case-control, 10-year retrospective, longitudinal study. We evaluated routine coagulation factors in 138 glioma patients (45 Females/93 Males; median [range] age, 56.4 [27-82] years; 64 non-recurrent/74 recurrent) and, for comparison, in 56 relapsing-remitting MS patients (41 Females/15 Males; 40.8 [25-62] years, 35 stable/21 active) and 23 controls (16 Females/7 Males; 41.7 [24-62] years) as well as Neutrophil-to-lymphocyte ratio (NLR) in subgroups of 127 glioma patients, 33 MS patients and 23 healthy controls. Secondly, we assessed whether these indicators could be predictive of overall (OS) and progression-free survival (PFS) in glioma patients. NLR, d-dimer, Antithrombin III and Factor VIII were significantly higher in glioma patients compared to both MS patients and controls (p<0.0001 for all). ROC curves confirmed that either NLR, Antithrombin III or Factor VIII were moderately accurate biomarkers (0.7<AUC<0.9) for glioma patients compared to other two groups whereas d-dimer was a moderately accurate marker for glioma only when compared to controls. In multivariable analysis, NLR ≥ 4.3 (median) (HR 1.53 [95 % CI 1.04-2.26], p=0.03) together with the Karnofsky Performance Status (KPS) ≥ 80 (median) (0.46 [0.31-0.69], p<0.0001) and use of steroids (1.75 [1.19-2.57], p=0.004) resulted independent predictors of OS while only KPS was independently associated with PFS. Our study showed increased levels of either NLR, Antithrombin III, Factor VIII, or d-dimer in glioma patients compared to MS patients and controls, where the first three represented moderately accurate biomarkers for this cancer. Among these markers, only NLR was found to be predictive for OS along with severe disability and steroid therapy.
Identifiants
pubmed: 34345234
doi: 10.17179/excli2021-3831
pii: 2021-3831
pmc: PMC8326499
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1152-1169Informations de copyright
Copyright © 2021 Koudriavtseva et al.
Références
Curr Med Chem. 2017;24(27):3002-3009
pubmed: 28521700
Neuron. 1991 Apr;6(4):575-81
pubmed: 2015093
Glioma. 2018 Jul-Aug;1(4):132-135
pubmed: 30272052
J Thromb Haemost. 2015 Oct;13(10):1833-42
pubmed: 26264493
J Neurooncol. 2015 Sep;124(2):299-305
pubmed: 26100546
J Neurooncol. 2017 May;132(3):463-471
pubmed: 28332000
Curr Opin Neurol. 2015 Jun;28(3):206-19
pubmed: 25887768
Front Neurol. 2019 Jan 14;9:1175
pubmed: 30692962
Lancet Neurol. 2019 Apr;18(4):376-393
pubmed: 30797715
Neural Regen Res. 2019 Dec;14(12):2043-2053
pubmed: 31397331
Int J Mol Sci. 2020 Aug 13;21(16):
pubmed: 32823572
Eur J Cancer. 2012 Jul;48(10):1532-42
pubmed: 22227039
J Neurooncol. 2011 Mar;102(1):35-41
pubmed: 20607353
Brain. 2016 May;139(Pt 5):1458-71
pubmed: 27020328
Anticancer Res. 2013 May;33(5):2093-8
pubmed: 23645760
Cerebrovasc Dis. 2014;37(1):64-75
pubmed: 24401164
Neuro Oncol. 2014 Dec;16(12):1645-51
pubmed: 24987133
Oncol Lett. 2019 Feb;17(2):2516-2522
pubmed: 30719120
J Clin Neurosci. 2018 Aug;54:7-13
pubmed: 29801989
Int J Mol Sci. 2016 Jan 11;17(1):
pubmed: 26761005
Folia Neuropathol. 2003;41(1):23-7
pubmed: 12862392
Nat Rev Immunol. 2013 Jan;13(1):34-45
pubmed: 23222502
Mult Scler J Exp Transl Clin. 2018 Nov 28;4(4):2055217318813183
pubmed: 30515298
J Neurooncol. 2019 Sep;144(2):249-264
pubmed: 31346902
Trends Cardiovasc Med. 1999 Oct;9(7):185-92
pubmed: 10881749
EXCLI J. 2018 May 28;17:505-512
pubmed: 30034313
Haematologica. 2012 Aug;97(8):1158-64
pubmed: 22371182
CNS Neurosci Ther. 2019 Aug;25(8):876-883
pubmed: 30912613
World Neurosurg. 2019 Jul;127:e261-e267
pubmed: 30898756
J Neurooncol. 2018 Jan;136(1):173-180
pubmed: 29076002
J Clin Diagn Res. 2017 May;11(5):CC01-CC04
pubmed: 28658752
Nat Med. 2019 Dec;25(12):1822-1832
pubmed: 31806905
Front Biosci (Landmark Ed). 2018 Jan 1;23:1060-1081
pubmed: 28930589
Front Neurol. 2014 Jul 07;5:119
pubmed: 25071707
Cell Physiol Biochem. 2018;45(4):1663-1676
pubmed: 29490291
Neurol Res. 2018 Nov;40(11):917-922
pubmed: 30074469
J Neurooncol. 2018 Jul;138(3):527-535
pubmed: 29594657
J Exp Ther Oncol. 2008;7(4):285-90
pubmed: 19227008
J Clin Pathol. 2010 Sep;63(9):818-22
pubmed: 20671046
Curr Neurol Neurosci Rep. 2017 Jan;17(1):5
pubmed: 28138871
Semin Thromb Hemost. 2014 Sep;40(6):621-33
pubmed: 25099191
J Neurooncol. 2015 Sep;124(2):151-6
pubmed: 26123362
Br J Cancer. 2015 Dec 1;113(11):1642
pubmed: 26625224
Neuro Oncol. 2014 Jul;16(7):896-913
pubmed: 24842956
Nature. 2008 Jul 24;454(7203):436-44
pubmed: 18650914
Asian Pac J Cancer Prev. 2017 Dec 29;18(12):3287-3291
pubmed: 29286221
Radiat Oncol. 2015 Oct 31;10:222
pubmed: 26520780
J Thromb Thrombolysis. 2015 Jan;39(1):55-9
pubmed: 25006010
World Neurosurg. 2019 Jan;121:e621-e629
pubmed: 30292037
J Neurol. 2013 Dec;260(12):3150-7
pubmed: 24122061
World Neurosurg. 2018 Nov;119:e710-e716
pubmed: 30092479
BMC Neurol. 2019 Feb 12;19(1):23
pubmed: 30755165
Front Neurol. 2015 Mar 04;6:40
pubmed: 25788892
J Neurooncol. 2013 Jul;113(3):345-352
pubmed: 23670054
Indian J Pathol Microbiol. 2010 Oct-Dec;53(4):605-10
pubmed: 21045378
Medicine (Baltimore). 2018 Aug;97(31):e11774
pubmed: 30075606
Mol Neurobiol. 2019 Sep;56(9):6071-6079
pubmed: 30719642
Int J Neurosci. 2016 Aug;126(8):700-6
pubmed: 26000934
J Neurosci Res. 2017 Oct;95(10):2080-2085
pubmed: 28316070
J Clin Oncol. 2010 Apr 10;28(11):1963-72
pubmed: 20231676
Clin Adv Hematol Oncol. 2017 Aug;15(8):580-583
pubmed: 28949944
Wien Klin Wochenschr. 2011 Apr;123(7-8):199-203
pubmed: 21442202
Neurol Sci. 2014 Nov;35(11):1737-41
pubmed: 24847961
Clin Cancer Res. 2004 Feb 15;10(4):1312-7
pubmed: 14977830
Lancet Neurol. 2006 Nov;5(11):937-48
pubmed: 17052661
Cancer Med. 2016 Aug;5(8):1783-90
pubmed: 27236861
Thromb Res. 2014 May;133 Suppl 2:S1-9
pubmed: 24862126
Onco Targets Ther. 2018 Feb 23;11:955-965
pubmed: 29503570
Mult Scler Relat Disord. 2017 Nov;18:213-217
pubmed: 29141813
Semin Thromb Hemost. 2014 Apr;40(3):325-31
pubmed: 24599439